Loading animation
  • Home
  • About us View About us's child pages
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages
      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages
      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages
      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages
      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages
      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us

Please use the arrows to navigate to the sub pages

  • About us View About us's child pages

    About us

    Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys®  technology.

    Explore this section
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages

    What we do

    Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.

    Explore this section
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages

      MED3000

      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages

      TPR100

      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages

      Other products

      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages

      Products FAQ's

      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages

    Investor centre

    Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.

    WEBCASTS

    Explore this section
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages

      Videos and webcasts

      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages

      Shareholder centre

      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages

    Media

    This section contains the latest RNS, news and videos.

    Explore this section
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
  • About us View About us's child pages
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages
      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages
      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages
      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages
      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages
      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
    Group of happy friends

    MED2005 FAQs

    • Home
    • What we do
    • Products FAQ's
    • MED2005 FAQs

    • What is the difference between Eroxon®, MED2002, MED2005 and MED3000?

      Eroxon® is the registered and suggested brand name for Futura’s topical gel for ED, though potential distributors may choose to use other brand names.

      MED3000 is now the codename for a formulation of DermaSys® developed specifically for the treatment of ED.

      MED2005 or MED2002 are the codenames used by Futura for all proprietary formulations containing Glyceryl Trinitrate (GTN).

    • How can I apply for the trial?

      Currently there are no requirements for patients however as per the regulatory update on 22nd October 2020, the Company is pleased to confirm that following its third pre-submission meeting with FDA, there was preliminary agreement on the design and scope of a small supplementary study, known as "FM71" subject to the issue of the final meeting minutes. Detailed planning for the study has now commenced and Futura is targeting Q1 2021 patient enrolment depending on completion of the final study protocol for FM71.

      Patients interested in participating will be able to find details in due course on ClinicalTrials.gov.

    • What are your plans for MED2005 post Phase 3?

      Futura is pursuing the medical device regulatory pathway for its proprietary transdermal formulation MED3000 in the US and Europe.

    • What were the results of the European Phase 3 study, FM57?

      Results of the FM57 study can be found here

    You may also be interested in

    MED3000 Overview
    MED3000 Clinical Programme
    MED3000 Commercial potential
    Futura Medical logo

    ©2021 Futura Medical

    • Sitemap
    • Contact us
    • Accessibility
    • Terms of use
    • Privacy & cookies policies

    Designed and developed by
    jonesandpalmer.co.uk